Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a vaccine protect the most vulnerable? a study probes immune response in transplant patients

NCT ID NCT04757883

Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study looks at how well kidney transplant recipients respond to COVID-19 vaccination. Researchers will measure neutralizing antibodies and specialized immune cell activity in blood samples taken after the second vaccine dose. The goal is to see if these patients, who often have weakened immune systems due to anti-rejection medications, develop effective protection against the virus.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
COVID-19 vaccine (licensed in France) given as part of routine care
What this could lead to
If successful, this could help tailor vaccination strategies for immunocompromised patients, potentially improving their protection against COVID-19.
What could go wrong
This is a small observational study, so results may not apply broadly. Kidney transplant patients often have weaker vaccine responses, and the study does not test new vaccines or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

37 people

The number who actually took part.

Started

Feb 2021

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

kidney transplants

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, 18 years of age or older * Patient vaccinated against SARS-CoV-2 as part of routine care * Kidney or pancreatic kidney transplant * Transplantation for more than 3 months * Subject affiliated to a social protection health insurance * Subject able to understand the objectives and risks of the research and to give signed and dated informed consent Exclusion Criteria: * History of anaphylactic shock or known allergy to PEG * Known history of COVID or positive Covid serology in the 3 months prior to vaccination * Contraindication to an intramuscular injection * Impossibility to give informed information about the subject (subject in an emergency situation, difficulties in understanding the subject, ...) * Subject under safeguard of justice * Subject under guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney transplant recipients are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplant recipients

Contacts and locations

Locations

  • Caillard Sophie

    Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.